title: Comparison of 6-18F-fluorodopamine PET with 123I-metaiodobenzylguanidine and 111in-pentetreotide scintigraphy in localization of nonmetastatic and metastatic pheochromocytoma.
abstract: We compared functional imaging modalities including PET with 6-(18)F-fluorodopamine ((18)F-DA) with (123)I-metaiodobenzylguanidine ((123)I-MIBG) and somatostatin receptor scintigraphy (SRS) with (111)In-pentetreotide in nonmetastatic and metastatic pheochromocytoma (PHEO).
  
  
  METHODS
  We studied 25 men and 28 women (mean age +/- SD, 44.2 +/- 14.2 y) with biochemically proven nonmetastatic (n = 17) or metastatic (n = 36) PHEO. Evaluation included anatomic imaging with CT or MRI and functional imaging that included at least 2 nuclear medicine modalities: (18)F-DA PET, (123)I-MIBG scintigraphy, or SRS. Sensitivity of functional imaging versus anatomic imaging was assessed on a per-patient and a per-region basis.
  
  
  RESULTS
  For this available cohort, on a per-patient basis overall sensitivity (combined for nonmetastatic and metastatic PHEO) was 90.2% for (18)F-DA PET, 76.0% for (123)I-MIBG scintigraphy, and 22.0% for SRS. On a per-region basis, overall sensitivity was 75.4% for (18)F-DA PET, 63.4% for (123)I-MIBG scintigraphy, and 64.0% for SRS.
  
  
  CONCLUSIONS
  If available, (18)F-DA PET should be used in the evaluation of PHEO, because it is more sensitive than (123)I-MIBG scintigraphy or SRS. If (18)F-DA PET is not available, (123)I-MIBG scintigraphy (for nonmetastatic or adrenal PHEO) and SRS (for metastatic PHEO) should be the first alternative imaging methods to be used.
authors.affiliation: Reproductive Biology and Adult Endocrinology Program, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892-1109, USA.
authors.forename: Ioannis
authors.initials: I
authors.lastname: Ilias
authors.forename: Clara C
authors.initials: CC
authors.lastname: Chen
authors.forename: Jorge A
authors.initials: JA
authors.lastname: Carrasquillo
authors.forename: Millie
authors.initials: M
authors.lastname: Whatley
authors.forename: Alexander
authors.initials: A
authors.lastname: Ling
authors.forename: Ivica
authors.initials: I
authors.lastname: Lazúrová
authors.forename: Karen T
authors.initials: KT
authors.lastname: Adams
authors.forename: Shiromi
authors.initials: S
authors.lastname: Perera
authors.forename: Karel
authors.initials: K
authors.lastname: Pacak
mesh_terms: D019797:3-Iodobenzylguanidine; D003952:Diagnostic Imaging / Q000379:methods; D004298:Dopamine / Q000031:analogs & derivatives*; D005260:Female; D005462:Fluorine Radioisotopes; D006801:Humans; D007205:Indium Radioisotopes / Q000494:pharmacology*; D007457:Iodine Radioisotopes; D008297:Male; D009362:Neoplasm Metastasis; D010673:Pheochromocytoma / Q000000981:diagnostic imaging*; D049268:Positron-Emission Tomography / Q000379:methods*; D011877:Radionuclide Imaging / Q000379:methods*; D019275:Radiopharmaceuticals; D012189:Retrospective Studies
chemical_list: D005462:Fluorine Radioisotopes; D007205:Indium Radioisotopes; D007457:Iodine Radioisotopes; D019275:Radiopharmaceuticals; D019797:3-Iodobenzylguanidine; C029253:6-fluorodopamine; D004298:Dopamine
references.citation: N Engl J Med. 1999 Jun 17;340(24):1872-9
references.pmid: 10369850
references.citation: J Nucl Med. 2003 Nov;44(11):1767-74
references.pmid: 14602858
references.citation: Radiology. 2002 Feb;222(2):507-12
references.pmid: 11818620
references.citation: Endocr Rev. 1994 Jun;15(3):356-68
references.pmid: 8076587
references.citation: J Clin Endocrinol Metab. 2004 Feb;89(2):479-91
references.pmid: 14764749
references.citation: Clin Nucl Med. 2000 Jun;25(6):440-2
references.pmid: 10836692
references.citation: Horm Metab Res. 2005 Dec;37(12):722-8
references.pmid: 16372224
references.citation: J Nucl Med. 1992 Jun;33(6):1125-31
references.pmid: 1597727
references.citation: Anticancer Res. 1997 May-Jun;17(3B):1589-92
references.pmid: 9179199
references.citation: Laryngoscope. 2004 Mar;114(3):434-40
references.pmid: 15091215
references.citation: Eur J Nucl Med Mol Imaging. 2003 May;30(5):689-94
references.pmid: 12618904
references.citation: Q J Nucl Med. 1995 Dec;39(4 Suppl 1):3-8
references.pmid: 9002740
references.citation: Ann Intern Med. 1995 Jul 15;123(2):101-9
references.pmid: 7778821
references.citation: Exp Clin Endocrinol Diabetes. 1998;106(5):373-6
references.pmid: 9831301
references.citation: Q J Nucl Med. 1995 Dec;39(4 Suppl 1):145-9
references.pmid: 9002775
references.citation: Radiology. 2004 Feb;230(2):423-8
references.pmid: 14752186
references.citation: Q J Nucl Med. 1996 Dec;40(4):365-71
references.pmid: 9050342
references.citation: Eur J Nucl Med. 2001 Sep;28(9):1421-9
references.pmid: 11585303
references.citation: Hypertension. 2001 Jul;38(1):6-8
references.pmid: 11463751
references.citation: J Clin Endocrinol Metab. 2001 Feb;86(2):685-93
references.pmid: 11158032
references.citation: Endocr Relat Cancer. 2006 Jun;13(2):525-33
references.pmid: 16728579
references.citation: Ann Intern Med. 2001 Feb 20;134(4):315-29
references.pmid: 11182843
references.citation: J Clin Endocrinol Metab. 2001 Feb;86(2):895-902
references.pmid: 11158063
references.citation: Clin Nucl Med. 1995 Mar;20(3):243-9
references.pmid: 7750219
references.citation: Radiology. 1999 Jul;212(1):35-41
references.pmid: 10405717
references.citation: J Postgrad Med. 1994 Apr-Jun;40(2):85-7
references.pmid: 8737560
references.citation: Nucl Med Commun. 2006 Jan;27(1):31-6
references.pmid: 16340721
references.citation: Eur J Surg. 2001 Nov;167(11):866-70
references.pmid: 11848244
references.citation: Nucl Med Commun. 2006 Jul;27(7):583-7
references.pmid: 16794519
references.citation: J Clin Oncol. 2007 Jun 1;25(16):2262-9
references.pmid: 17538171
references.citation: Endocrine. 2003 Apr;20(3):307-11
references.pmid: 12721512
references.citation: Clin Nucl Med. 2005 Aug;30(8):579-81
references.pmid: 16024963
references.citation: Int J Urol. 1999 Mar;6(3):119-24
references.pmid: 10226821
references.citation: J Nucl Med. 2007 Dec;48(12):1940-4
references.pmid: 18006611
references.citation: Endocr Rev. 2004 Aug;25(4):568-80
references.pmid: 15294882
references.citation: Eur J Endocrinol. 1999 Dec;141(6):619-24
references.pmid: 10601965
references.citation: J Clin Endocrinol Metab. 2001 Aug;86(8):3641-6
references.pmid: 11502790
references.citation: Endocr Res. 2004 Nov;30(4):931-4
references.pmid: 15666847
references.citation: AJNR Am J Neuroradiol. 1997 Jun-Jul;18(6):1073-80
references.pmid: 9194434
references.citation: J Nucl Med. 1995 Jan;36(1):1-6
references.pmid: 7799058
references.citation: Eur J Nucl Med. 1993 Aug;20(8):716-31
references.pmid: 8404961
references.citation: Clin Nucl Med. 1996 Sep;21(9):695-9
references.pmid: 8879869
references.citation: Am J Med. 1987 Oct;83(4):770-2
references.pmid: 3674064
references.citation: Fam Cancer. 2005;4(1):61-8
references.pmid: 15883712
references.citation: Q J Nucl Med. 1999 Sep;43(3):217-23
references.pmid: 10568137
references.citation: Ann Surg Oncol. 2006 Feb;13(2):187-97
references.pmid: 16418883
references.citation: J Clin Endocrinol Metab. 2003 Sep;88(9):4083-7
references.pmid: 12970267